A national shortage of measles vaccines will continue for at least another month.
That means most people born before 1970 won’t be able to follow public health advice and get a shot before travel outside Canada — unless they cross the border to get the shot.
Some New Brunswickers have been doing just that, according to Joleen Fowler, a pharmacy technician at Walgreens in Calais, Maine.
“We’ve had a few people come over and ask, you know, if they were able to get it from us, and we were able to oblige,” she said.
Merck, Canada’s supplier, had expected the shortage of its MMR II vaccine, for measles, mumps and rubella, for the private market such as travel clinics, to end by April 19, but now lists May 15 as the estimated end date on Health Canada’s Drug Shortages website.
Merck has also posted an anticipated shortage of its ProQuad vaccine from April 26 until Aug. 30. ProQuad is used for the prevention of measles, mumps, rubella, and chickenpox in children between 12 months and 12 years old.
An increase in demand for measles vaccines, due to a rise in cases and outbreaks across the country and the world, led to the shortage, Merck Canada said in an email to CBC News Friday.
Remaining doses of the company’s measles vaccines are being reserved for publicly funded childhood immunization programs.
Working to ensure consistent supply for public programs
Asked whether Merck still expects to be able to fully meet the demands of these public immunization programs, the company replied via email: “We continue to work diligently with all relevant stakeholders, including provincial and federal health authorities, to provide a consistent supply of MMR®II vaccines in a timely manner.
“Our priority remains firmly focused on ensuring the availability of this vaccine to